Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Almac Expands US & UK Commercial Facilities

Published: Tuesday, October 22, 2013
Last Updated: Tuesday, October 22, 2013
Bookmark and Share
Investments of over $20m enhance Almac’s commercial facilities on both sides of the Atlantic.

With the opening of a new commercial packaging facility in the US and enhanced processing capabilities at the company’s Headquarters in Craigavon, UK, investments in the past year has substantially transformed the commercial business unit of Almac.

In Feb 2013, with FDA approval, Almac opened their US commercial packaging facility providing quality driven, flexible packaging solutions for both solid oral dosage forms and biopharmaceutical products.

Meanwhile, expansion continued at Almac’s UK commercial manufacturing and packaging facilities, with the completion of a US client led capital project in support of a key global product launch. This expansion has added significant capacity for commercial fluid bed drying and high speed encapsulation.

Additionally, in response to growing demand from a number of Japanese partners for enhanced flexibility related to larger blister sizes and requirement for non permeability and environmental protection, investment has also been made in blistering technology with product humidity control.

Due to record sales, growth in one of Almac’s client’s key products and entry into new markets including China, the most recent commercial expansion completed at the UK site was a client led second investment in dedicated facilities, doubling sachet output to 250 million sachets per annum.

David Downey, VP, Commercial Operations notes: “Almac continues to grow in partnership with our clients and is developing a strong reputation for the delivery of complex, time sensitive capital projects in support of growing, innovative products. This level of commercial investment demonstrates our commitment to building long term, strategic relationships.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,900+ scientific posters on ePosters
  • More than 4,200+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Almac Group Addresses Industry Demand For Multiparticulate Drug Products
In response to increasing client demand for multiparticulate drug delivery systems, Almac Group is providing fluid-bed processing and encapsulation services to its global partners from its UK development and commercial manufacturing facilities.
Monday, October 12, 2015
Novozymes Biopharma Announces Collaboration with Almac
Combined service offers drug development companies efficiencies in time and resource.
Tuesday, October 22, 2013
Almac Announces Further Expansion and 229 New Jobs
Dual expansion with completion of a new non-GMP drug development facility.
Monday, June 17, 2013
Almac and TTP Labtech form Alliance in Fluorescence Lifetime Technology
This will give customers of either party access to a broad range of biological applications coupled with the next generation of microplate reader technology.
Tuesday, January 08, 2013
Almac Doubles Analytical Capacity in US Headquarters
New Lab investment includes polymorph and salt screening and solid form development.
Friday, February 10, 2012
Scientific News
Spero Therapeutics Announces $30 Million Series B Preferred Financing
Company has announced financing of $30 million to support development of novel therapies to treat gram-negative bacterial infections.
Keeping Tumor Growth at Bay
Engineers at Washington University in St. Louis found a way to keep a cancerous tumor from growing by using nanoparticles of the main ingredient in common antacid tablets.
Future of Medicine Could be Found in a Tiny Crystal Ball
A Drexel University materials scientist has discovered a way to grow a crystal ball in a lab. Not the kind that soothsayers use to predict the future, but a microscopic version that could be used to encapsulate medication in a way that would allow it to deliver its curative payload more effectively inside the body.
Improving Delivery of Poorly Soluble Drugs Using Nanoparticles
A technology that could forever change the delivery of drugs is undergoing evaluation by the Technology Evaluation Consortium™ (TEC). Developed by researchers at Northeastern University, the technology is capable of creating nanoparticle structures that could deliver drugs into the bloodstream orally – despite the fact that they are normally poorly soluble.
Faster Drug Discovery?
Startup develops more cost-effective test for assessing how cells respond to chemicals.
New Mechanism of Antitumor Action Identified
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.
Nanoparticles Deliver Tumor Suppressors to Damaged Livers
UT Southwestern Medical Center chemists have successfully used synthetic nanoparticles to deliver tumor-suppressing therapies to diseased livers with cancer, an important hurdle scientists have been struggling to conquer.
Experimental Combination Surprises with Anti-HIV Effectiveness
A compound developed to protect the nervous system from HIV surprised researchers by augmenting the effectiveness of an investigational antiretroviral drug beyond anything expected.
A New Type of Anticancer Agent
Success in the development of a ?-tubulin specific inhibitor.
Nanoparticles Proven Effective Against Antibiotic-Resistant “Superbugs”
In the ever-escalating evolutionary battle with drug-resistant bacteria, humans may soon have a leg up thanks to adaptive, light-activated nanotherapy developed by researchers at the University of Colorado Boulder.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,200+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!